Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
US9309212B2 · kind B2 · utility
0Cited by
8References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2012 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | May 22, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.